Clinical trials: Esophageal Squamous Cell Carcinoma
Esophageal Cancer
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006472
- Testing
- carboplatin, fluorouracil, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Medstar Health Research Institute
Esophageal Cancer
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so it can be…
- Trial name
- NCT00047112
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 73 sites in Belgium, France and 2 more
- Volunteers
- 195 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Esophageal Squamous Cell Carcinoma, Immunotherapy
Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC.
Conduct a retrospective and prospective study to confirm the association between blood cells counts and the efficacy and safety in immunochemotherapy in patients with advanced esophageal cancer.
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Chemotherapy
- Trial name
- NCT06125262
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Esophageal Cancer
Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc
The goal of this observational study is to to clarify the focus of lymph node dissection during esophagectomy.. The main question[s] it aims to answer is: provide a basis for accurate staging and the relationship between OS and…
- Trial name
- NCT05604664
- Where
- China
- Volunteers
- 1,727 people
- Sponsor
- Yongtao Han
Glioblastoma, Squamous Cell Carcinoma
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO.
- Conditions
- Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
- Trial name
- NCT05974410
- Testing
- AVM0703, Hydrocortisone, Proton pump inhibitor
- Sponsor
- AVM Biotechnology Inc
Achalasia, Epidermoid Carcinoma
Epidermoid Cancer Development in Esophageal Achalasia
Esophageal achalasia is a precancerous condition for epidermoid carcinoma; incidence and risk factors for cancer development are not defined.
- Trial name
- NCT03546998
- Testing
- Clinical instrumental examinations
- Where
- Italy
- Volunteers
- 681 people
- Sponsor
- Sandro Mattioli
ESCC, Lymph Node Metastasis
Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma
This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC).
- Conditions
- ESCC, Lymph Node Metastasis, Radiomics
- Trial name
- NCT07050576
- Testing
- The prediction model of lymph node metastasis in early esophageal squamous cell carcinoma
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Thoracic Esophageal Squamous Cell Carcinoma
Improve the Treatment of Thoracic Esophageal Cancer
The purpose of this study is 1. To compare the effects of the two types of thoracic esophageal cancer lymphadenectomy on the staging and prognosis of resectable esophageal cancer, which defined by the International Association of…
- Trial name
- NCT01137123
- Testing
- adjuvant chemotherapy, standard two field Lymphadenectomy, Total two field Lymphadenectomy
- Where
- China
- Volunteers
- 301 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00004897
- Testing
- recombinant interferon alfa, cisplatin, fluorouracil
- Where
- United States
- Sponsor
- Northwestern University
Esophageal Squamous Cell Carcinoma
A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya
Background: Esophageal cancer is the sixth leading cause of cancer deaths worldwide. Two primary cell types, squamous cell carcinoma and adenocarcinoma, account for most cases.
- Trial name
- NCT00901173
- Where
- Kenya
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma (ESCC), Infiltration
Infiltration Pattern of Locally Advanced ESCC
Prospectively collect the pathological records of ESCC patients, and analyse the infiltration pattern of ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Infiltration, Tumour
- Trial name
- NCT07567716
- Testing
- Esophagectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.
- Trial name
- NCT07549269
- Testing
- The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- Where
- 3 sites in China
- Volunteers
- 387 people
- Sponsor
- Sichuan University
Esophageal Cancer
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
Disease recurrence and metastasis are common after curative treatment for patients with esophageal cancer. Thus, it is important to identify the risk factors to predict disease recurrence and metastasis.
- Trial name
- ECTOP-2005 (NCT05443841)
- Testing
- pleural lavage
- Where
- 11 sites in China
- Volunteers
- 385 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma, Immunotherapy
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab plus concurrent chemotherapy as neoadjuvant approach for patients with opearble esophageal squamous cell carcinoma.
- Trial name
- NCT04225364
- Testing
- camrelizumab, Paclitaxel for injection (albumin-bound), Cisplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Esophageal Squamous Cell Carcinoma
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying…
- Trial name
- NCT06561178
- Testing
- molecular residual disease detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Esophageal Cancer
Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
The goal of this observational study is to learn about in health conditions of ESCC. The main question[s] it aims to answer are: •Lymph node metastasis(LNM) in cervical paraesophageal or supraclavicular which influence OS more.
- Trial name
- ECPLNMvsSLNM (NCT06165094)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)
Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown.
- Trial name
- NCT01269970
- Testing
- 18-FDG-PET-CT
- Where
- Belgium
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital